荷兰食管癌质子放疗国家适应证方案
荷兰多学科工作组基于文献回顾、预测模型评估与外部验证,制定食管癌质子放疗的国家适应证方案(NIPP)。方案以2年死亡率预测模型为基础进行模型化选择,要求质子放疗较光子放疗的2年死亡率绝对下降≥5%,并纳入体力状态与分期标准。该方案已于2021年获荷兰放射肿瘤学会及荷兰卫生保健研究所批准,正通过ProTRAIT登记系统开展全国实施与前瞻性评估。
要点
- 以2年死亡率预测模型进行模型化选择,要求质子放疗较光子放疗绝对降低≥5%。
- 预测模型以平均心脏剂量(MHD)和肿瘤大体体积(GTV)为预测因子。
- 附加标准包括WHO体力状态0-2分,并排除cT4、cN3或cM1。
核心结论
- 荷兰成功实施了食管癌质子放疗的全国性适应证方案,该方案基于模型化选择定义报销资格。
- NIPP使预期从质子放疗获益的个体患者能够获得报销。
研究设计与样本
- 成立全国多学科工作组,通过文献回顾、预测模型评估、外部模型验证和利益相关方参与制定NIPP方案。
- 将原用于肺癌的2年死亡率预测模型在接受根治性(dCRT)或新辅助(nCRT)放化疗的食管癌患者中进行外部验证。
主要发现
- 心脏事件和总生存被确定为最具临床相关性的终点。
- 无现有模型满足模型化选择的质量标准。
- 肺癌2年死亡率预测模型在更新截距(两个队列)和斜率(nCRT)后表现良好。
关键数值与推荐
- 模型化选择定义为质子放疗较光子放疗的2年死亡率预测绝对下降≥5%。
- 预测模型使用平均心脏剂量(MHD)和肿瘤大体体积(GTV)作为预测因子。
- 附加选择标准包括WHO体力状态0-2分,并排除cT4、cN3或cM1状态。
临床怎么用
- 符合NIPP标准的食管癌患者可申请质子放疗报销,选择依据为模型预测的2年死亡率绝对下降≥5%。
- 全国实施和前瞻性结局评估正在通过ProTRAIT登记系统进行。
局限性
- 原文未报告模型验证的具体性能指标(如AUC、校准度数值)。
- 原文未报告预测模型在食管癌队列中的样本量。
- 原文未报告NIPP实施后的前瞻性结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chemoradiotherapy (CRT) plays a key role in treating esophageal cancer (EC) but is associated with significant toxicity. Proton radiotherapy (PRT) may reduce this risk by limiting radiation dose to organs at risk. In the Netherlands, PRT is reimbursed only when eligibility criteria defined in a National Indication Protocol for Proton Therapy (NIPP) are met. This study describes the development and implementation of such a protocol for EC based on model-based selection. MATERIALS AND METHODS: A national multidisciplinary working group was formed aiming to develop the NIPP protocol through literature review, evaluation of prediction models, external model validation, and stakeholder engagement. RESULTS: Cardiac events and overall survival were identified as the most clinically relevant endpoints. As no existing models met the quality criteria for model-based selection, a validated 2-year mortality prediction model originally developed for lung cancer was externally validated in EC patients treated with definitive (dCRT) or neoadjuvant (nCRT) CRT. The model performed well after updates to the intercept (both cohorts) and slope (nCRT). Model-based selection was defined as a ≥ 5 % predicted absolute reduction in 2-year mortality with PRT versus photon radiotherapy, using Mean Heart Dose (MHD) and Gross Tumor Volume (GTV) as predictors. Additional selection criteria included WHO performance status 0-2 and exclusion of cT4, cN3, or cM1 status. The NIPP was approved by the Dutch Society of Radiation Oncology in June 2021 and by the Dutch Health Care Institute in October 2021. National implementation and prospective outcome evaluation are ongoing via the ProTRAIT registry. CONCLUSION: A national indication protocol enabling model-based selection for PRT in EC was successfully implemented in the Netherlands. The NIPP describes eligibility criteria for proton therapy reimbursement and enables reimbursement for individual patients who are expected to benefit from PRT.
引用
- Muijs CT, Klaver YLB, Nuyttens J, et al. National indication protocol for proton radiotherapy in esophageal cancer patients in the Netherlands. Radiother Oncol. 2025. PMID: 41005671. doi:10.1016/j.radonc.2025.111164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。